{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:10:14Z","timestamp":1793693414498,"version":"4.5.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to evaluate the efficacy and safety of hetrombopag in the management of chemotherapy-induced thrombocytopenia (CIT) among patients with solid tumors, utilizing a retrospective cohort study design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study population comprised patients experiencing CIT due to chemotherapy for solid tumors, who received treatment at the General Hospital of Northern Theater Command from January 2023 to December 2024. Participants were categorized into four distinct cohorts based on their treatment regimens: the recombinant human thrombopoietin (rhTPO) monotherapy group, the hetrombopag monotherapy group, the combination therapy group (hetrombopag with rhTPO), and the recombinant human interleukin-11 (rhIL-11) monotherapy group. The primary outcomes evaluated included treatment response rate, alterations in platelet count (PLT), time to PLT recovery, differences in PLT counts pre- and post-treatment; secondary outcome measured encompassed rates of platelet transfusion, and incidence of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included a total of 187 patients, distributed as follows: 64 in the rhTPO group, 37 in the hetrombopag group, 36 in the combination therapy group, and 50 in the rhIL-11 group. The hetrombopag + rhTPO group exhibited a significantly higher treatment response rate (P&amp;lt;0.05) compared to the other three groups. Furthermore, this group showed superior PLT levels on days 7 and 14, a greater increment in PLT post-treatment, and the shortest median time to PLT recovery to \u2265100\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L (P&amp;lt;0.05). Hetrombopag monotherapy demonstrated non-inferior PLT dynamics and treatment response rates compared to rhTPO\/rhIL-11 (P&amp;gt;0.05). The four groups exhibited comparable PLT transfusion rates and a AEs incidence (P&amp;gt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of hetrombopag and rhTPO therapy exhibits superior efficacy compared to monotherapy in the treatment of CIT in patients with solid tumors. This combination therapy is associated with rapid elevation of platelet counts and a shortened recovery period, while maintaining a favorable safety profile. Furthermore, hetrombopag monotherapy has shown efficacy comparable to that of rhTPO and recombinant human interleukin-11 (rhIL-11), thereby supporting its recommendation for clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1670029","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:17:51Z","timestamp":1761628671000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of hetrombopag in the treatment of chemotherapy-related thrombocytopenia in solid tumors: a retrospective study"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuan","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"B1","first-page":"2360","article-title":"A multicenter, randomized phase II trial on the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors","author":"Ma","year":"2023","journal-title":"Eur Congress Internal Med Abstract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1182\/blood-2023-182634","article-title":"Effectiveness and safety of hetrombopag in the management of radiotherapy-induced thrombocytopenia in patients with gynecological Malignancies","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.1004-2806.2023.09.010","article-title":"Jiang R.Clinical efficacy and safety of hetrombopag in the treatment of chronic primary immune thrombocytopenia","volume":"9","author":"Zhang","year":"2023","journal-title":"J Clin Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.07.002","article-title":"Expert consensus on the diagnosis and treatment of cancer drug-related thrombocytopenia in China (2023 edition)","volume":"103","year":"2023","journal-title":"Chin Med J"},{"key":"B6","year":"2024","journal-title":"CSCO Guidelines for the Diagnosis and Management of Thrombocytopenia Caused by Antineoplastic Therapy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-8179.2019.18.914","article-title":"Expert consensus on the diagnosis and treatment of chemotherapy-induced thrombocytopenia in China (2019 edition)","volume":"46","year":"2019","journal-title":"Chin J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13595","article-title":"The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic Malignancies","volume":"106","author":"Shaw","year":"2021","journal-title":"Eur J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13809","article-title":"Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist","volume":"22","author":"Xie","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological Malignancies:an international, randomised, double- blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.970978","article-title":"Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial","volume":"13","author":"Cui","year":"2022","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic Malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164490","article-title":"Combination of thrombopoietin receptor agonist and recombinant human thrombopoietin for treating cancer therapy-induced thrombocytopenia","volume":"140","author":"Yan","year":"2022","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1182\/blood-2023-179702","article-title":"Efficacy of hetrombopag in treatment of cancer therapy-induced thrombocytopenia in lymphoma and multiple myeloma patients","volume":"142","author":"Huang","year":"2023","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn115356-20220809-00229","article-title":"Clinical application guidelines for hetrombopag","volume":"31","year":"2022","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1670029\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:17:54Z","timestamp":1761628674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1670029\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1670029"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1670029","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"article-number":"1670029"}}